

[Fig. 1]



- C: Control group, NS: Nelumbinis Semen treatment group
- P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group
- * P < 0.05 versus control group







C: Control group, NS: Nelumbinis Semen treatment group


P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group


* P < 0.05 versus control group

[Fig. 3]










N: Normal group not exposed to CMS, C: Control group exposed to CMS

NS: Nelumbinis Semen treatment group, P: Fluoxetine treatment group


SW Hypericum perforatum treatment group

* P < 0.05 versus control group or normal group

[Fig. 4]




Body weight change for 9 weeks under CMS




N: Normal group, C: Control group, NS: Nelumbinis Semen treatment group

P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group

* P < 0.05 versus control group






N: Normal group, C: Control group, NS: Nelumbinis Semen treatment group

P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group


*P < 0.05 versus control group

[Fig. 6]
Start latency in open field test



- N. Normal group, C. Control group, NS: Nelumbinis Semen treatment group
- P. Fluoxetine treatment group, SW: Hypericum perforatum treatment group
- * P < 0.05 versus control group


[Fig. 7] Rearing in open field test



- N: Normal group, C: Control group, NS: Nelumbinis Semen treatment group
- P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group

^{*}P < 0.05 versus control group

[Fig. 8]
Grooming time in open field test




N: Normal group, C: Control group, NS: Nelumbinis Semen treatment group

P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group

* P < 0.01 versus control group

[Fig. 9]
The effect of *Nelumbinis Semen* on sexual behavior




N: Normal group, C: Control group, NS: Nelumbinis Semen treatment group

P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group

* P < 0.05 versus normal group

[Fig. 10]

Post ejaculation interval under CMS




N: Normal group, C: Control group, NS: Nelumbinis Semen treatment group

P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group

* P < 0.05 versus normal group

[Fig. 11]
Serotonine release effect of NS




N: Normal group, C: Control group, NS: Nelumbinis Semen treatment group

P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group

* P < 0.05 versus normal group, ** P < 0.01 versus normal group


[Fig. 12]
Serotonine release of NS under CMS



- N: Normal group, C: Control group, NS: Nelumbinis Semen treatment group
- P: Fluoxetine treatment group, SW: Hypericum perforatum treatment group
- * P < 0.05 versus normal group, # P < 0.05 versus control group


[Fig. 13]

Receptor Binding: [3H]8-OH-DPAT Autoradiography



[Fig. 14]






CA2	(Mean: mean binding intensity)			7.1.	
	Size	Mean	SEM	Mean %	Change %
N	n=4	8.893	0.892	106	61
С	n=3	8.4	0.188	100	0
NS	n=2	9.567	0.891	114	141
Р	n=3	7.378	0.297	88	12↓
SW	n=4	9.64	0.817	115	15↑


[Fig. 15]





CA3	(Mean: mear	(Mean: mean binding intensity)			ī .
	Size	Mean	SEM	Mean %	Change %
N	n=4	10.351	0.806	110	101
С	n=3	9.425	0.81	100	0
NS	n=4	10.708	0.813	114	14↑
Р	n=3	9.216	0.462	98	2 ↓
SW	n=4	9.795	0.747	104	41

[Fig. 16]



Frontal co	rtex (I-II)	(Mean: mean binding intensity)				
	Size	Mean	SEM	Mean %	Change %	
N	n=4	6.553	0.537	115	151	
C	n=3	5.711	0.865	100	0	
NS	n=4	6.314	0.451	111	111	
P	n=3	3.09	0.323	54	46↓	
sw	n=4	8.773	0.908	154	54↑	

N: Normal group, C: Control group exposed to CMS


NS: Nelumbinis Semen treatment group, P: Fluoxetine treatment group

SW: Hypericum perforatum treatment group

* P < 0.05 versus fluoxetine treatment group


[Fig. 17]

Hypothalamus



Hypothalaı	nus	(Mean: mean binding intensity)				
	Size	Mean	SEM	Mean %	Change %	
N	n=4	11.793	1.782	159	59↑	
<u>C</u>	n=4	7.428	2.596	100	0	
NS	n=2	10.526	3.367	142	421	
P	n=2	12.701	2.021	171	71↑	
sw	n=4	10.721	0.904	144	44↑	

[Fig. 18]



[Fig. 19]

The comparison of intensity of 4 spots in different treatment group

Spot 1-Adenylosuccinate synthetase			(Mean: nor v	an: nor volume), n=3		
we in the second	Mean	SEM	Mean %	Change %		
N	0.293	0.102	227	127 ↑		
С	0.129	0.043	100	0		
NS	0.207	0.063	160	1601		
Р	0.032	0.012	25	75 ↓		
Spot 2-Cyt	Spot 2-Cytochrome C oxidase			(Mean: nor volume), n=3		
en de la carra de	Mean	SEM	Mean %	Change %		
N	0.156	0.034	208	1081		
С	0.075	0.016	100	0		
NS	0.166	0.025	221	1211		
P	0.123	0.025	164	64 1		
Spot 3-MA	Spot 3-MAP kinase 2		(Mean: nor v	volume), n=3		
	Mean	SEM	Mean %	Change %		
N	0.068	0.012	139	391		
С	0.049	0.019	100	0		
NS	0.088	0.026	178	78↑		
P	0.117	0.047	237	137↑		
Spot 4-Ald	Spot 4-Aldehyde dehydrogenase I			volume), n=3		
	Mean	SEM	Mean %	Change %		
N	0.144	0.017	100	0		
С	0.144	0.015	100	0		
NS	0.172	0.037	119	19↑		
P	0.091	0.025	63	37↓		
	<u> </u>	;	<u> </u>	:		

N: normal, C: control, NS: Nelumbinis Semen, P: prozac (fluoxetin)